StreetInsider.com News Articles

Form 8-K Coya Therapeutics, Inc. For: Oct 14

Wed, 14 Oct 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20261014/27184304.html

Coya plans open-label extension of ALS trial, delays FTD study

Wed, 14 Oct 2026 08:00:26 -0400

Coya Therapeutics (NASDAQ: COYA) announced plans to initiate an open-label extension (OLE) of its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), according to a press release from the Houston-based company.

The OLE is planned in response to requests from ALSTARS investigators and study participants. Eligible participants who complete the 48-week treatment period will have the opportunity to continue receiving COYA 302, while allowing the collection of longer-term efficacy and safety data. Coya expects the OLE to begin in November 2026, as the first cohort completes the 48-week treatment period.

Concurrent with the OLE initiation,

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

Wed, 14 Oct 2026 08:00:00 -0400

OLE planned in response to requests from ALSTARS investigators and participants
Eligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302
Cash runway guidance remains unchanged into the second half of 2027, beyond anticipated ALSTARS topline data readout in early Q2

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial (NCT07161999)

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

Wed, 14 Oct 2026 08:00:00 -0400

OLE planned in response to requests from ALSTARS investigators and participants
Eligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302
Cash runway guidance remains unchanged into the second half of 2027, beyond anticipated ALSTARS topline data readout in early Q2

Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference

Tue, 13 Oct 2026 08:00:00 -0400

HOUSTON--(BUSINESS WIRE)--

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced the company will be participating in a panel discussion at Chardan's 10th Annual Healthcare Conference taking place on October 20 in New York.

Panel Details:

Title: Targeting Neurodegenerative & Neuromuscular Disease: ALS, DMD, Alzheimer's & Parkinson's
Time: 2:00 PM ET
Moderator: Keay Nakae, Senior Research Analyst at Chardan
Coya Participant: Fred Grossman, DO, President & Chief Medical Officer of Coya Therapeutics

Coya’s management team will be available for

Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference

Tue, 13 Oct 2026 08:00:00 -0400

HOUSTON--(BUSINESS WIRE)--

Panel Details:

Coya’s management team will be available for

H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Tue, 06 Oct 2026 07:05:32 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on Coya Therapeutics (NASDAQ: COYA).

The analyst commented: "Yesterday, Coya Therapeutics announced full enrollment of the planned 120 participants in the company’s Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the potential treatment of amyotrophic lateral sclerosis (ALS). Additional participants already engaged in active screening will be allowed to enroll in the trial if deemed eligible. Top-line data from the double-blind treatment phase are anticipated in early 2Q27, per prior timeline guidance. Study objectives include evaluation of efficacy,

Form 8-K Coya Therapeutics, Inc. For: Oct 05

Mon, 05 Oct 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20261005/27146200.html

Coya Therapeutics completes enrollment in Phase 2/3 ALS trial

Mon, 05 Oct 2026 08:00:44 -0400

Coya Therapeutics, Inc. (NASDAQ: COYA) has completed enrollment of 120 participants in its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), according to a company statement.

The trial is a randomized, multicenter, double-blind, placebo-controlled study. Participants are assigned 1:1:1 to one of two dosing regimens of COYA 302 or placebo during a 24-week double-blind treatment phase. Patients who complete that phase then enter a 24-week blinded active-treatment extension. The company said additional participants already in active screening may still be allowed to enroll if deemed eligible.

Topline data from the 24-week double-blind phase are expected

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Mon, 05 Oct 2026 08:00:00 -0400

120th participant has been enrolled in ALSTARS trial achieving target enrollment

Additional eligible participants already in active screening will be allowed to enroll

Topline data from 24-week double-blind treatment phase on track for early Q2 2027

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced full enrollment of the planned 120 participants in the Company’s Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the potential treatment

Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Mon, 05 Oct 2026 08:00:00 -0400

120th participant has been enrolled in ALSTARS trial achieving target enrollment

Additional eligible participants already in active screening will be allowed to enroll

Topline data from 24-week double-blind treatment phase on track for early Q2 2027

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced full enrollment of the planned 120 participants in the Company’s Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the potential treatment

H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Fri, 25 Sep 2026 06:51:03 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on Coya Therapeutics (NASDAQ: COYA).

The analyst commented: "COYA 302 key proof-of-concept mid-stage trial reaches enrollment milestone, with data release timeline intact. In a recent press release, Coya Therapeutics announced that the 100th patient has been enrolled in the company’s ongoing Phase 2/3 ALSTARS trial (NCT07161999) evaluating COYA 302, Coya’s combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment of amyotrophic lateral sclerosis (ALS). Based on current enrollment trends, Coya anticipates completing full enrollment of 120 participants in sufficient time to permit reporting top-line data early

Form 8-K Coya Therapeutics, Inc. For: Sep 15

Tue, 15 Sep 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260915/27061597.html

Coya Therapeutics reaches 100 enrollees in ALS drug trial

Tue, 15 Sep 2026 08:00:45 -0400

Coya Therapeutics, Inc. (NASDAQ: COYA) announced that the 100th participant has been enrolled in its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).

The company said it expects to complete full enrollment of 120 participants within the coming weeks, with topline data anticipated in early Q2 2027, based on current screening and enrollment rates.

The ALSTARS trial is a randomized, multi-center, double-blind, placebo-controlled study. Participants are randomized 1:1:1 to one of two dosing regimens of COYA 302 or placebo during a 24-week double-blind treatment phase, followed by a 24-week blinded active-treatment extension phase. The primary

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Tue, 15 Sep 2026 08:00:00 -0400

Based on current screening and enrollment rates, topline data anticipated in early Q2 2027
Additional participants continue to roll over into the active extension arm of the trial
COYA 302 has received FDA Fast Track designation for the treatment of ALS

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced that the 100th patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, Coya’s

Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS

Tue, 15 Sep 2026 08:00:00 -0400

Based on current screening and enrollment rates, topline data anticipated in early Q2 2027
Additional participants continue to roll over into the active extension arm of the trial
COYA 302 has received FDA Fast Track designation for the treatment of ALS

H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Mon, 24 Aug 2026 06:51:51 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on Coya Therapeutics (NASDAQ: COYA).

The analyst commented: "We draw investors' attention to the fact that Coya Therapeutics plans to make progress with key clinical initiatives over the course of the remainder of 2026, including the following: (1) achievement of full enrollment in the ALSTARS Phase 2 trial of lead candidate COYA 302 for treatment of amyotrophic lateral sclerosis (ALS) in 2H26, with top-line data slated for release in 2027; (2) initiation of a Phase 2a study evaluating COYA 302 for the treatment of frontotemporal dementia (FTD) in

Coya Therapeutics, Inc. (COYA) Tops Q2 EPS by 42c

Tue, 11 Aug 2026 09:38:49 -0400

Coya Therapeutics, Inc. (NASDAQ: COYA) reported Q2 EPS of ($0.28), $0.42 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $240 thousand.

For earnings history and earnings-related data on Coya Therapeutics, Inc. (COYA) click here.

Form 10-Q Coya Therapeutics, Inc. For: Jun 30

Tue, 11 Aug 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26901927.html

Form 10-Q Coya Therapeutics, Inc. For: Jun 30

Tue, 11 Aug 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26901927.html

Form 8-K Coya Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260811/26901879.html

Form 8-K Coya Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 08:04:00 -0400

si-local-file:///var/storage/secattach/20260811/26901879.html

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Tue, 11 Aug 2026 08:00:00 -0400

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.

“During the second quarter, we made notable progress advancing our lead program, COYA 302,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. “Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Tue, 11 Aug 2026 08:00:00 -0400

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Tue, 11 Aug 2026 08:00:00 -0400

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update.